LeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at StockNews.com

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

Separately, Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a research report on Tuesday, March 7th.

LeMaitre Vascular Stock Performance

LMAT opened at $47.97 on Friday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of 51.58, a P/E/G ratio of 4.20 and a beta of 0.98. The stock’s 50 day moving average price is $47.90 and its 200-day moving average price is $47.81. LeMaitre Vascular has a one year low of $38.32 and a one year high of $56.38.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). The firm had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $40.99 million. LeMaitre Vascular had a net margin of 12.77% and a return on equity of 9.00%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 EPS. As a group, analysts predict that LeMaitre Vascular will post 1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 6,414 shares of the stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $50.94, for a total transaction of $326,729.16. Following the sale, the insider now directly owns 3,791 shares of the company’s stock, valued at approximately $193,113.54. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 12.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Captrust Financial Advisors lifted its stake in LeMaitre Vascular by 555.3% in the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 522 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in LeMaitre Vascular in the 3rd quarter valued at approximately $62,000. Vestcor Inc acquired a new stake in LeMaitre Vascular in the 4th quarter valued at approximately $114,000. Lazard Asset Management LLC increased its holdings in LeMaitre Vascular by 48.8% in the 2nd quarter. Lazard Asset Management LLC now owns 2,563 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 841 shares during the last quarter. Finally, Strs Ohio acquired a new stake in LeMaitre Vascular in the 3rd quarter valued at approximately $136,000. 86.85% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

(Get Rating)

LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.